Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myasthenia Gravis × CK-2017357 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 9 zilucoplan 7 efgartigimod alfa 7 telitacicept 6 Rituximab 6 Cyclophosphamide 6 fludarabine 5 eculizumab 5 Prednisone 5 Pyridostigmine Bromide 4 Hizentra 4 ravulizumab 3 Tacrolimus 3 HBM9161 3 Amifampridine 3 thymoglobulin 2 inebilizumab 2 Prednisolone 2 Mycophenolic Acid 2 Immunoglobulins, Intravenous 2 tofacitinib 1 tocilizumab 1 satralizumab 1 sargramostim 1 rhoA GTP-Binding Protein 1 remibrutinib 1 prednylidene 1 iptacopan 1 gamma-Globulins 1 deltacortene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01268280 2019-09-24

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

Cytokinetics

Phase 2 Terminated

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡